Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
The US pharmaceutical industry has been experiencing fluctuating levels of growth during the last couple of years. However, the market is expected to stabilize in the coming years. The Patient Protection and Affordable Care Act (or Obamacare) can be attributed to the expected growth in the pharmaceutical industry. Revenues for pharmaceutical manufacturers however, is likely going to be restricted by Medicare discounts and rebates.
The generics sector in the US pharmaceutical industry is one of the biggest in the world and accounts for nearly a third of the global generics industry. A matter of concern for the US pharmaceutical industry is that a large number of branded drugs in the US, worth nearly USD 40 billion, are going to be coming off patent by the end of 2016. This is likely to boost the growth of the US generics industry though.
Aruvian Research analyzes the US pharmaceutical industry in a Porter's Five Forces Strategy analysis and looks at the bargaining power of buyers and suppliers, the competitive rivalry within the industry, the threat of new entrants to the US pharma industry and the threat of substitutes to the industry.
Apart from the Porter's Five Forces Strategy Analysis, we also analyze the US pharmaceutical industry through an industry profile, an analysis of the OTC pharmaceutical market in the US, the generic drugs market in the US, industry value, market share in the industry, market trends and challenges and an industry outlook.